How to Participate

Your Doctor. Your Partner.

We encourage you to ask your gastroenterologist or primary care physician about participating in the Etro Studies.


10 topics to talk with your doctor about1

  1. Might I be eligible to participate in an Etro Study?
  2. How does this study compare to my other options?
  3. Do I have the symptoms of moderately to severely active Ulcerative Colitis (UC) or Crohn’s disease?
  4. What types of medications have I previously used?
  5. What are the potential side effects or risks of the study medication?
  6. What are the potential benefits?
  7. How could participating in the study affect my daily life?
  8. What are my other treatment choices, if I chose not to participate in this study?
  9. How does the treatment I would receive in this study compare with the other treatment choices?
  10. What if I want to stop participating in the study?

Print and take this with you to your doctor

 

Information for Physicians

The Etro Studies are a family of Phase III clinical trials, and a program of firsts: the first head-to-head studies in UC, and the first Phase III program to use standardized, centralized endoscopic scoring in Crohn’s disease and UC.

The Etro Studies will examine the safety and efficacy of etrolizumab in patients who are still experiencing symptoms of Crohn’s disease or UC despite being previously treated with corticosteroids, immunosuppressants, and/or tumor necrosis factor (TNF) inhibitors. Some studies will evaluate etrolizumab in patients who are anti-TNF naïve, and others in patients who have had an inadequate response, loss of response, or intolerance to anti-TNF therapy.

The Etro Studies will compare etrolizumab to placebo or adalimumab. Parts of these studies are double- blinded and will last for up to 82 weeks. The open-label extension studies for UC and Crohn’s will provide study medication to eligible patients who meet the safety criteria.

For more information, visit etrostudiesresearch.com.

 

 

Reference: 1. www.nih.gov/health/clinicaltrials/basics.htm#5

 


  • Print